Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes

Medicine & Life Sciences

• Costs and Cost Analysis 23%
• Delivery of Health Care 42%
• Dipeptidyl-Peptidase IV Inhibitors 91%
• Glucose 43%
• Health Care Costs 6%
• Hospitalization 5%
• Inpatients 6%
• Japan 6%
• Length of Stay 5%
• Ocular Vision 6%
• Outpatients 5%
• Pharmaceutical Preparations 28%
• Propensity Score 8%
• Single-Payer System 14%
• Sodium-Glucose Transporter 2 Inhibitors 100%
• Symporters 94%
• Type 2 Diabetes Mellitus 51%
• Universal Health Care 11%
• Universal Health Insurance 10%